Therapeutic development of angiogenesis‐targeting drugs has been most successful in cancer and ocular diseases, with the vast majority of approved drugs focusing on the inhibition of VEGF‐mediated downstream signaling (Formica et al., 2021; Kong et al., 2017). The gene discussed is VEGFA; the disease is cancer.